Truist raised the firm’s price target on Viking Therapeutics to $120 from $38 and keeps a Buy rating on the shares. The firm is citing “further evidence” of VK2735 being a “best in class” GLP-1 weight loss drug profile. VK2735 appears to be about twice as effective in weight loss compared to tirzepatide and numerically superior to even retatrutide, a triple agonist, all the while exhibiting superior tolerability, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics 6.47M share Secondary priced at $85.00
- Viking Therapeutics price target raised to $116 from $46 at Oppenheimer
- Viking Therapeutics announces $350M common stock offering
- Viking Therapeutics price target raised to $120 from $50 at Maxim
- Viking Therapeutics price target raised to $115 from $37 at Raymond James
